
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics is facing a key event with the completion of enrollment for their P3 Dravet syndrome study, and given the recent 36-month data for zorevunersen demonstrating non-seizure improvement, it seems likely ZOLGENSMA followed by SPINRAZA or other drugs. Their lead candidate for Dravet syndrome, zorevunersen, could generate potential peak annual sales exceeding $1 billion and we feel positively about its ASO as a treatment for Autosomal Dominant Optic Atrophy. Considering a WACC of 13%, our 12-month price target is $35 per share for this development stage company and we see potential for future revenue streams from other targets being pursued by Stoke's broad applicability in addressing hundreds of disease states.
Bears say
Stoke Therapeutics is facing high operating losses and large net losses, making it financially unstable. While its TANGO platform and lead asset zorevunersen offer potential in treating genetic disorders, there are significant risks associated with intellectual property rights and regulatory approvals. Additionally, the company relies on data from third-party CROs, which could negatively affect its drug development process. Furthermore, there are concerns about potential share dilution for shareholders and the high ownership of Skorpios Trust, which could result in stock price volatility. Overall, the company's uncertain financials and potential risks in its drug development process make us hold a negative view on Stoke Therapeutics' stock.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares